CAPRICOR THERAPEUTICS, INC. (CAPR) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Win.
33/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseCAPR / S&P -20.79% / 15.20% |
LoseCAPR / S&P CAPR unavailable / 15.00% |
WinCAPR / S&P 54.09% / 50.40% |
| 2026-Q12/3 |
WinCAPR / S&P 5.34% / -4.33% |
LoseCAPR / S&P CAPR unavailable / 11.30% |
WinCAPR / S&P 69.34% / 27.70% |
| 2025-Q42/3 |
WinCAPR / S&P 300.28% / 2.65% |
LoseCAPR / S&P CAPR unavailable / 9.00% |
WinCAPR / S&P 96.52% / 13.40% |
| 2025-Q31/3 |
LoseCAPR / S&P -27.39% / 8.12% |
LoseCAPR / S&P CAPR unavailable / 4.61% |
WinCAPR / S&P 71.57% / 13.45% |
| 2025-Q21/3 |
LoseCAPR / S&P 4.64% / 10.94% |
LoseCAPR / S&P CAPR unavailable / 4.83% |
WinCAPR / S&P 78.65% / 10.63% |
| 2025-Q11/3 |
LoseCAPR / S&P -31.23% / -4.27% |
LoseCAPR / S&P CAPR unavailable / 4.98% |
WinCAPR / S&P 65.06% / 10.57% |
| 2024-Q41/3 |
LoseCAPR / S&P -9.27% / 2.41% |
LoseCAPR / S&P -11.55% / 5.25% |
WinCAPR / S&P 38.55% / 6.15% |
| 2024-Q32/3 |
WinCAPR / S&P 218.87% / 5.89% |
WinCAPR / S&P 65.33% / 5.89% |
LoseCAPR / S&P -12.07% / 6.11% |
| 2024-Q21/3 |
LoseCAPR / S&P -29.75% / 4.28% |
WinCAPR / S&P 187.15% / 5.38% |
LoseCAPR / S&P -23.93% / 5.12% |
| 2024-Q11/3 |
WinCAPR / S&P 38.85% / 10.56% |
LoseCAPR / S&P CAPR unavailable / 5.71% |
LoseCAPR / S&P -29.06% / 5.59% |
| 2023-Q41/3 |
WinCAPR / S&P 42.98% / 11.69% |
LoseCAPR / S&P CAPR unavailable / 6.81% |
LoseCAPR / S&P -29.66% / 7.78% |
| 2023-Q31/3 |
LoseCAPR / S&P -28.45% / -3.27% |
LoseCAPR / S&P CAPR unavailable / 7.52% |
WinCAPR / S&P 2.65% / -5.03% |
| 2023-Q22/3 |
WinCAPR / S&P 13.27% / 8.74% |
LoseCAPR / S&P CAPR unavailable / 9.50% |
WinCAPR / S&P 12.50% / -8.57% |
| 2023-Q12/3 |
WinCAPR / S&P 9.33% / 7.50% |
LoseCAPR / S&P CAPR unavailable / 10.77% |
WinCAPR / S&P 21.88% / -15.69% |
| 2022-Q41/3 |
LoseCAPR / S&P -35.67% / 7.56% |
LoseCAPR / S&P CAPR unavailable / 11.88% |
WinCAPR / S&P 35.63% / -17.99% |
| 2022-Q32/3 |
WinCAPR / S&P 71.92% / -4.88% |
LoseCAPR / S&P CAPR unavailable / 13.47% |
WinCAPR / S&P 15.31% / -1.41% |
| 2022-Q21/3 |
WinCAPR / S&P 1.75% / -16.10% |
LoseCAPR / S&P CAPR unavailable / 13.71% |
LoseCAPR / S&P 0.00% / 11.04% |
| 2022-Q11/3 |
WinCAPR / S&P 17.06% / -4.60% |
LoseCAPR / S&P CAPR unavailable / 15.97% |
LoseCAPR / S&P -9.43% / 42.23% |
| 2021-Q40/3 |
LoseCAPR / S&P -27.11% / 11.03% |
LoseCAPR / S&P CAPR unavailable / 15.00% |
LoseCAPR / S&P CAPR unavailable / 96.40% |
| 2021-Q30/3 |
LoseCAPR / S&P -21.64% / 0.58% |
LoseCAPR / S&P CAPR unavailable / 10.77% |
LoseCAPR / S&P CAPR unavailable / 69.42% |
| 2021-Q21/3 |
WinCAPR / S&P 9.62% / 8.55% |
LoseCAPR / S&P -46.71% / 6.58% |
LoseCAPR / S&P CAPR unavailable / 51.81% |
| 2021-Q11/3 |
WinCAPR / S&P 36.44% / 6.17% |
LoseCAPR / S&P -82.78% / -1.06% |
LoseCAPR / S&P CAPR unavailable / 7.39% |
| 2020-Q40/3 |
LoseCAPR / S&P -34.67% / 12.15% |
LoseCAPR / S&P -69.13% / -3.72% |
LoseCAPR / S&P CAPR unavailable / -33.42% |
| 2020-Q31/3 |
WinCAPR / S&P 14.13% / 8.93% |
LoseCAPR / S&P -66.84% / -2.04% |
LoseCAPR / S&P CAPR unavailable / -27.10% |
| 2020-Q21/3 |
WinCAPR / S&P 283.33% / 20.54% |
LoseCAPR / S&P -60.24% / -0.46% |
LoseCAPR / S&P CAPR unavailable / -27.11% |
| 2020-Q11/3 |
WinCAPR / S&P -6.25% / -19.60% |
LoseCAPR / S&P -36.06% / 3.47% |
LoseCAPR / S&P CAPR unavailable / -14.75% |
| 2019-Q40/3 |
LoseCAPR / S&P -65.41% / 9.07% |
LoseCAPR / S&P -39.87% / 5.36% |
LoseCAPR / S&P CAPR unavailable / 2.99% |
| 2019-Q31/3 |
WinCAPR / S&P 11.45% / 1.70% |
LoseCAPR / S&P -4.54% / 5.02% |
LoseCAPR / S&P CAPR unavailable / 0.21% |
| 2019-Q20/3 |
LoseCAPR / S&P -29.36% / 4.30% |
LoseCAPR / S&P -5.33% / 6.64% |
LoseCAPR / S&P CAPR unavailable / 8.65% |
| 2019-Q11/3 |
WinCAPR / S&P 14.63% / 13.65% |
LoseCAPR / S&P -0.01% / 8.12% |
LoseCAPR / S&P CAPR unavailable / 14.29% |
| 2018-Q40/3 |
LoseCAPR / S&P -60.95% / -13.52% |
LoseCAPR / S&P -15.71% / 9.05% |
LoseCAPR / S&P CAPR unavailable / 18.23% |
| 2018-Q30/3 |
LoseCAPR / S&P -21.64% / 7.71% |
LoseCAPR / S&P -37.90% / 10.21% |
LoseCAPR / S&P CAPR unavailable / 19.06% |
| 2018-Q20/3 |
LoseCAPR / S&P -1.47% / 3.43% |
LoseCAPR / S&P -44.05% / 9.03% |
LoseCAPR / S&P CAPR unavailable / 14.46% |
| 2018-Q10/3 |
LoseCAPR / S&P -13.92% / -0.76% |
LoseCAPR / S&P -59.01% / 7.68% |
LoseCAPR / S&P CAPR unavailable / 12.46% |
| 2017-Q40/3 |
LoseCAPR / S&P -47.85% / 6.64% |
LoseCAPR / S&P -50.41% / 7.03% |
LoseCAPR / S&P CAPR unavailable / 13.82% |
| 2017-Q31/3 |
WinCAPR / S&P 265.06% / 4.48% |
LoseCAPR / S&P -42.73% / 5.68% |
LoseCAPR / S&P CAPR unavailable / 17.57% |
| 2017-Q20/3 |
LoseCAPR / S&P -75.44% / 3.09% |
LoseCAPR / S&P -40.47% / 4.83% |
LoseCAPR / S&P CAPR unavailable / 17.74% |
| 2017-Q11/3 |
WinCAPR / S&P 27.07% / 6.07% |
LoseCAPR / S&P -25.90% / 3.67% |
LoseCAPR / S&P CAPR unavailable / 13.32% |
| 2016-Q40/3 |
LoseCAPR / S&P -17.90% / 3.82% |
LoseCAPR / S&P -27.53% / 2.09% |
LoseCAPR / S&P CAPR unavailable / 7.05% |
| 2016-Q30/3 |
LoseCAPR / S&P -17.97% / 3.85% |
LoseCAPR / S&P -27.28% / 0.20% |
LoseCAPR / S&P CAPR unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | CAPR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 60.19% | 20.78% |
| Annualized return | 60.19% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | CAPR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 117.75% | 83.14% |
| Annualized return | 16.84% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | CAPR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -72.36% | 319.30% |
| Annualized return | -12.07% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |